fNIRS Studies of Music Intervention of Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04212897|
Recruitment Status : Not yet recruiting
First Posted : December 30, 2019
Last Update Posted : December 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Other: Music Therapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Parallel assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Masking Description:||Patients and the outcomes assessor are blinded in this study|
|Official Title:||Therapeutic Benefits of Music for Parkinson's Disease: a fNIRS Study Protocol for Controlled Trial|
|Estimated Study Start Date :||January 2020|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||January 2022|
Experimental: Music Therapy
This group will be asked to practice a rhythmic auditory SFT intervention task at home.
Other: Music Therapy
Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, "Moonlight over the Lotus Pond" by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions.
No Intervention: No Music Therapy
This group will not engage in an intervention task at home and will be asked to continue their normal daily routine.
- Change from Functional Near-infrared Spectroscopy from baseline [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]An ETG-4000 fNIRS system will be used to measure hemoglobin (HBO2) levels in the participant as they perform finger motor control timing assessments. A change, specifically a reduction of HBO2 activation, from baseline measurements indicates reduced cortical activation and suggests improved PD-related symptoms.
- Change in Synchronous Finger Motor Control Timing Abilities from baseline [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]Participants will be asked to tap their right index finger on a standard QWERTY keyboard "1" key when a visual cue appears. The response time for tapping the "1" key, in response to seeing the visual cue, will be measured to assess motor-timing control. Accuracy of response will be dependent on minimizing early or delayed taps (measured in milliseconds) in congruence with the determined rhythm. A change in score, particularly greater accuracy in timing, from baseline indicates better or improved motor control performance.
- Change in Continuous Finger Motor Control Timing Abilities from baseline [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]Participants will be asked to tap their right index finger on a standard QWERTY keyboard "1" key when a visual cue appears. The participants will then be asked to maintain the tapping rhythm without the visual cue for 15 seconds. The timing of tapping the "1" key, without the visual cue, will be measured to assess motor-timing control. Accuracy of response will be dependent on minimizing early or delayed taps (measured in milliseconds) in congruence with the determined rhythm. A change in score, particularly greater accuracy in timing, from baseline indicates better or improved motor control performance.
- Change in Unified Parkinson Disease Rating Scale (UPDRS) from baseline [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]UPDRS objectively assesses the severity of PD based off the disease's burden on the individual and can describe disease progression and treatment response. A total of 42 ratings are split between multiple categories. Examples of categories measured include mental impairments (mood and intelligence), activities in daily living (speech, salivation, level of independence to perform normal tasks such as turning in bed), motor skills (facial, tremor severity in extremities, rigidity) and other complications. Each category has a 0-4 rating determined by the examiner and summed, where a higher score reflects greater disability (maxed at 195 points). A change in the score, i.e. lower score from baseline, indicates beneficial effects of the intervention.
- Montreal Cognitive Assessment (MoCA) [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]MoCA assesses for an individual's cognitive abilities including orientation, concentration and attention, executive functions, memory, conceptual thinking, calculations, language, and visuo-constructional skills. The test is administered for 10-minutes as a one-page 30-point test. The point distribution is as follows. A short-term memory recall task with five nouns and delayed recall after five minutes (5 points). A clock drawing task (3 points) and a three-dimensional cube copy (1 point) are used to assess visuospatial abilities. Executive functioning is measured using the Trail Making B task (1 point), a phonemic fluency task (1 point), and a two-item abstraction task (2 points). A three-item confrontation naming task (3 points) as well as repeating two sentences with complex syntax (2 points) are used to measure language. Lastly, time and place orientation (6 points) is assessed. A larger total score (> or = 26 is normal) indicates healthy or normal cognition.
- n-Back Working Memory Assessment [ Time Frame: Week 0 (baseline), week 4 (during), week 8 (end), and week 12 (follow-up) ]The n-back task examines an individual's working memory and working memory capacity by employing a visuo-spatial continuous performance task. This study will use 3-back tasks that are delivered digitally and started with a digital countdown. The participant is asked to input a keystroke on standard QWERTY keyboard with their right-hand to indicate whether a target visual stimulus presented on the screen was identical to a previously shown stimulus presented 'n' trials ago. The stimulus will be a white square randomized into one of six positions on a black screen. The first cue stimulus will be presented on the screen for 3 s and the individual has 3 s to respond with a '1' keystroke to indicate 'same' or a '2' keystroke to indicate 'different'. A new stimulus will appear after a 1 s inter-stimulus interval. Each task will include responses to two sets of 15 and thus each assessment will last approximately 10 minutes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04212897
|Contact: Lanlan Pu, MD||180 9887 firstname.lastname@example.org|
|Contact: Zhanhua Liang, MD||180 9887 email@example.com|
|First Affiliated Hospital of Dalian Medical University|
|Dalian, Liaoning, China|
|Contact: Lanlan Pu, MD 180 9887 2622 firstname.lastname@example.org|
|Contact: Zhanhua Liang, MD 180 9887 7717 email@example.com|
|Sub-Investigator: Lanlan Pu, MD|
|Principal Investigator: Zhanhua Liang, MD|
|Principal Investigator:||Zhanhua Liang, MD||The First Affiliated Hospital of Dalian Medical University|
|Principal Investigator:||Bingwei Zhang, MD||The First Affiliated Hospital of Dalian Medical University|
|Principal Investigator:||Fengyu Cong, PhD||Dalian University of Technology|
|Principal Investigator:||William C Tang, PhD||University of California, Irvine|